Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Tax Provisions (2018 - 2025)

10x Genomics' Tax Provisions history spans 8 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Tax Provisions rose 63.43% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $3.6 million, down 26.18%, while the annual FY2025 figure was $3.6 million, 26.18% down from the prior year.
  • Tax Provisions for Q4 2025 was $1.1 million at 10x Genomics, up from -$733000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $2.5 million in Q2 2025 and bottomed at -$733000.0 in Q3 2025.
  • The 5-year median for Tax Provisions is $1.1 million (2023), against an average of $1.2 million.
  • The largest annual shift saw Tax Provisions surged 259.27% in 2022 before it tumbled 155.74% in 2025.
  • A 5-year view of Tax Provisions shows it stood at $2.5 million in 2021, then plummeted by 67.26% to $804000.0 in 2022, then skyrocketed by 192.79% to $2.4 million in 2023, then tumbled by 72.47% to $648000.0 in 2024, then surged by 63.43% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Tax Provisions are $1.1 million (Q4 2025), -$733000.0 (Q3 2025), and $2.5 million (Q2 2025).